Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumo-nia

Abstract

Infections potentially caused by DRSP may be treated by a method which comprises administering a pharmaceutical formulation comprising either: for an adult or older child patient from 800 to 1100 mg amoxycillin and from 100 to 150 mg clavulanate in a weight ratio between 6:1 and 10:1 inclusive; or for a paediatric patient from 30 to 40 mg/kg body weight of amoxycillin and from 3 to 8 mg/kg body weight of clavulanate in a weight ratio between 6:1 and 10:1 inclusive; in combination with a pharmaceutically acceptable carrier or excipient, three times a day(tid).

1 . The use of amoxycillin and clavulanate in the manufacture of a medicament for the empiric treatment of infections potentailly potentially caused by DRSP which medicament comprises: 
 for an adult or older child patient, from 800 to 1100 mg amoxycillin and from 100 to 150 mg clavulanate in a weight ratio between 6:1 and 10:1 inclusive; or    for a paediatric patient, from 30 to 40 mg/kg body weight of amoxycillin and from 3 to 8 mg/kg body weight of clavulanate in a weight ratio between 6:1 and 10:1 inclusive;    the medicament being taken three times a day (tid).    
     
     
         2 . A use as claimed in  claim 1  in which the ratio of amoxycillin to clavulanate is between 6.5:1 and 7.5:1 inclusive or 7.5:1 to 8.5:1.  
     
     
         3 . A use as claimed in  claim 1  in which the ratio of amoxycillin to clavulanate is about 7:1 or about 8:1.  
     
     
         4 . A use as claimed in any one of  claims 1  to  3  in which amoxycillin is in the form of amoxycillin trihydrate.  
     
     
         5 . A use as claimed in any one of  claims 1  to  4  in which clavulanate is in the form of potassium clavulanate.  
     
     
         6 . A use as claimed in  claim 1  in which the dosage quantity for paediatric patients is 35±10% mg/kg amoxycillin and 5±10% mg/kg clavulanate.  
     
     
         7 . A use as claimed in  claim 1  in which the dosage amount for an older child or an adult patient is 875±10% mg amoxycillin and 125±10% mg clavulanate or 1000±10% mg amoxycillin and 125±10% mg clavulanate.  
     
     
         8 . A use as claimed in any one of  claims 1  to  6  in which the formulation is adapted for administration to paediatric patients in the form of a powder or granular product for reconstitution into a suspension or solution and which comprises about 200 mg/unit dose volume of amoxycillin and 28.6 mg/unit dose volume of clavulanate or 400 mg/unit dose volume of amoxycillin and 57.2 mg/unit dose volume of clavulanate when reconstituted.  
     
     
         9 . A use as claimed in any one of  claims 1  to  5  or  claim 7  in which the formulation is in the form of tablets and adapted to provide about 875 mg amoxycillin and 125 mg clavulanate per unit dose.  
     
     
         10 . A method of treatment of infections potentially caused by DRSP which method comprises administering to a patient in need thereof a pharmaceutical formulation adapted for oral administration comprising either: 
 for an adult or older child patient from 800 to 1100 mg amoxycillin and from 100 to 150 mg clavulanate in a weight ratio between 6:1 and 10:1 inclusive; or    for a paediatric patient from 30 to 40 mg/kg body weight of amoxycillin and from 3 to 8 mg/kg body weight of clavulanate in a weight ratio between 6:1 and 10:1 inclusive;    in combination with a pharmaceutically acceptable carrier or excipient, three times a day (tid).